Mangoceuticals, Inc. (NASDAQ: MGRX)

Mangoceuticals, Inc., or MGRX, operates in the men's wellness telemedicine services and products industry. The company, founded in October 2021 and based in Texas, went public in March 2023, raising approximately $5 million in its initial public offering (IPO). Mangoceuticals specializes in connecting consumers to licensed healthcare professionals through its website for the provision of care via telehealth, a digital platform that allows customers to consult with healthcare professionals remotely and receive prescriptions for medications.

Two primary products drive Mangoceuticals' revenue: Mango ED and Mango GROW. Mango ED is a sublingual tablet designed to treat erectile dysfunction, while Mango GROW is a hair growth product. Both products are compounded at a related party pharmacy, Epiq Scripts, LLC, owned by the company's Chairman and CEO, Jacob D. Cohen. This relationship enables Mangoceuticals to control the quality and consistency of its products, ensuring they meet the highest standards of quality and purity.

Mangoceuticals generates revenue solely from the sale of its products to customers who purchase them online. The company does not charge subscription fees. The firm's telehealth platform, designed for convenience and accessibility, is a competitive advantage. This advantage attracts customers seeking a more convenient and accessible healthcare experience.

Mangoceuticals operates in the telehealth services, hair growth products, and erectile dysfunction products segments. The telehealth services segment connects consumers to licensed healthcare professionals for remote consultations and prescription services. The hair growth products segment features Mango GROW, designed to promote hair growth and prevent hair loss. The erectile dysfunction products segment includes Mango ED, a sublingual tablet for treating erectile dysfunction.

The company competes in the men's wellness telemedicine services and products industry, with its primary competitors being other companies offering telehealth services and products for men's wellness. Mangoceuticals' competitive advantages include its related party pharmacy, Epiq Scripts, LLC, and its telehealth platform, providing customers with a convenient and accessible healthcare experience.

Mangoceuticals' customers are individuals seeking a more convenient and accessible healthcare experience. The company's products are marketed and sold exclusively online, and the telehealth platform targets customers who prefer remote consultations and prescription services.

Mangoceuticals' product line includes Mango ED and Mango GROW. Mango ED is a sublingual tablet designed to treat erectile dysfunction, while Mango GROW is a hair growth product available in various dosages. Both products are compounded at Epiq Scripts, LLC, the related party pharmacy owned by the company's CEO.